{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '8. ECG evidence of acute ischemia, atrial fibrillation, or active conduction system', 'abnormalities with the exception of any of the following:', 'a.', 'First degree AV-block', 'b. Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)', 'c. Right bundle branch block', '9. Subject has severe vision impairment that, in the opinion of the Investigator, may', 'interfere with their ability to complete all trial requirements', '10. Subject has a seizure disorder that, in the opinion of the Investigator, may interfere with', 'their ability to complete all trial requirements.', '11. Active malignancy or any other cancer from which the subject has been disease-free for <', '2 years.', '12. Subject has a solid organ transplant and/or is currently receiving treatment with therapy', 'for immunosuppression, in the opinion of the Investigator.', '13. Subject has been previously diagnosed with human immunodeficiency virus (HIV),', 'hepatitis B, or hepatitis C infection.', '14. Subject has a history of a systemic eosinophilic illness and/or an eosinophil count >1,000', 'cells x106/L at the Screening Visit.', '15. Subject is currently participating or has participated in an interventional clinical trial (i.e.,', 'investigational product or device, stem cell therapy, gene therapy) within 30 days of the', 'Baseline Visit; or is currently enrolled in a non-interventional clinical trial (except for', 'SPIMM-300) at the Baseline Visit which, in the opinion of the Investigator, may be', 'potentially confounding to the results of the current trial (e.g. exercise therapy trial).', '16. Subject has previously received elamipretide (MTP-131), for any reason.', '17. Subject has a history of active substance abuse during the year before the Baseline Visit,', 'in the opinion of the Investigator.', '18. Subject has any prior or current medical condition that, in the judgment of the', 'Investigator, would prevent the subject from safely participating in and/or completing all', 'trial requirements.', '7.2.', 'PART 2 Eligibility', '7.2.1.', 'PART 2 Subject Continuation Criteria', 'A subject must meet all of the following PART 2 Continuation Criteria at the Week 24 Visit in', 'PART 1 to be eligible for PART 2:', '1. Subjects must continue to be able and willing to adhere to the trial requirements.', '2. Subject is appropriate to continue in PART 2 (i.e. subject was compliant in SPIMM-301),', 'in the opinion of the Investigator.', '3. Subject has not had a serious adverse event (SAE)/serious adverse device effect (SADE)', 'attributed to the elamipretide delivery system.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '54']['SPIMM-301 Version 4.0', '15 June 2018', '4. Subject has not permanently discontinued the elamipretide delivery system.', '7.3.', 'Prohibited Medications', 'The use of any other investigational drug except elamipretide is prohibited during the conduct of', 'the current trial.', 'The concurrent use of sacubitril (an antihypertensive drug used in combination with valsartan', 'marketed under the brand name, Entresto\u00ae, in the US and EU) is prohibited, due to a lack of', 'current information regarding possible drug interactions.', 'All attempts should be made to keep all medications, including over-the-counter treatments,', 'vitamins, or supplements constant during the SPIMM-301 trial and to not initiate new therapy', 'during the trial, unless in response to an AE. All concomitant medications will be recorded in the', 'source data and the Electronic Case Report Form (eCRF). Changes in dosages of current', 'medications (including over-the-counter vitamins or supplements) during the conduct of the trial', 'will be discouraged, unless required to treat an AE/ADE.', 'Subjects will be instructed to maintain their normal diet, daily caffeine, and fiber intake', 'throughout the trial period.', '7.4.', 'Criteria for Subject or Trial Discontinuation', '7.4.1.', 'Discontinuation of Subjects', 'Subjects may be discontinued from the trial for the following reasons:', 'Investigator Decision', '- The Investigator decides that the subject should be discontinued from the trial for', 'any reason (e.g., the eGFR is <30 mL/min/1.73 m\u00b2, using the MDRD study', 'equation).', 'Subject Decision', '-', \"The subject or the subject's designee, (e.g., parents or legal guardian), requests to\", 'be withdrawn from the trial.', '-', 'Subjects who withdraw should be explicitly asked about the contribution of', 'possible AEs/ADEs to their decision to withdraw consent, and any AE/ADE', 'information elicited should be documented.', 'Preferably the subject should withdraw consent in writing and, if the subject or', \"the subject's representative refuses or is physically unavailable, the clinical site\", \"should document and sign the reason for the subject's failure to withdraw consent\", 'in writing.', '- The subject is lost to follow-up after a reasonable number of attempts to contact', 'the subject (including documented phone calls and/or emails, and a certified', 'letter) have been completed.', 'Sponsor Decision', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '55']\n\n###\n\n", "completion": "END"}